Register now

To access the site, please provide the required information to verify that you are a Canadian healthcare professional and create an account. Once validated, this account can be used to log in to all myAstraZeneca websites for Canadian healthcare professionals. Please use the first and last name registered with your professional college.

Register

Already have an account?

If you already have an IQVIA OneKey account, log in to access the myAstraZeneca websites.

Login
EN FR

Choose BREZTRI AEROSPHERE for its power to reduce exacerbations in COPD1

BUDESONIDE (ICS), GLYCOPYRRONIUM (LAMA), AND FORMOTEROL (LABA) IN 1 pMDI DEVICE*

BREZTRI AEROSPHERE is indicated for the long-term maintenance treatment to reduce exacerbations of COPD and treat airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema, who are not adequately treated by a combination of an ICS/LABA or a combination of LAMA/LABA.

Learn more about BREZTRI AEROSPHERE and access resources designed to help physicians, pharmacists, and other healthcare professionals (HCPs) support patients below.

Key Trial

* Clinical significance has not been established.

COPD: chronic obstructive pulmonary disease; HCP: healthcare professional; ICS: inhaled corticosteroid; LABA: long-acting beta2-adrenergic agonist; LAMA: long-acting muscarinic antagonist. pMDI: pressurized metered-dose inhaler.

Reference:

  1. BREZTRI AEROSPHERE Product Monograph. AstraZeneca Canada Inc.
Back to Top